Ignite Creation Date:
2025-12-24 @ 10:16 PM
Ignite Modification Date:
2026-07-09 @ 5:21 AM
Study NCT ID:
NCT07065435
Status:
RECRUITING
Last Update Posted:
2025-07-15
First Post:
2025-07-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Sponsor:
Organization: